Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director · CHIEF EXECUTIVE OFFICER | March 21, 2025 | March 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date March 21, 2025 · Filed March 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2035-03-20 | Direct | 450,000 |
Reported balance
After 2025-03-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-21 · Grant · Acquired 450,000 · Balance 450,000 F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2025 Filed Mar 25, 2025 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-044347 · ownership.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 30,000 | $1.03 | $30,900.00 |
DisclosureSEC source: 0000950170-24-137860 · ownership.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,578 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.97 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range provided. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0000950170-24-028609 · ownership.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 16:07 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 3,000 | $2.86 | $8,580.00 |
DisclosureSEC source: 0001209191-23-046000 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,578 Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 12:28 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-043276 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 16:59 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 324,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-23-011247 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,000 Underlying: Common Stock · 324,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:29 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022570 · doc4.xml · derivative · entry 4 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: One half of the Restricted Stock Units vested on September 30, 2021 and the balance vested on March 31, 2022. F3 · derivative.expiration_date: One half of the Restricted Stock Units vested on September 30, 2021 and the balance vested on March 31, 2022. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:29 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022570 · doc4.xml · nonDerivative · entry 3 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,578 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:29 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 32,122 | $4.88 | $156,755.36 |
DisclosureSEC source: 0001209191-22-022570 · doc4.xml · nonDerivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,578 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:29 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-022570 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 16:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-22-021449 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. Read SEC document |
| September 30, 2021 Filed Oct 8, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060022 · doc4.xml · derivative · entry 3 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022. F3 · derivative.expiration_date: One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022. Read SEC document |
| September 30, 2021 Filed Oct 8, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 31,677 | $14.57 | $461,533.89 |
DisclosureSEC source: 0001209191-21-060022 · doc4.xml · nonDerivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,700 Read SEC document |
| September 30, 2021 Filed Oct 8, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060022 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 16:30 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 3,400 | $14.72 | $50,051.40 |
DisclosureSEC source: 0001209191-21-057784 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,377 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.749, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 17:47 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006358 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 16:49 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008793 · doc4.xml · derivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: One-half of the restricted stock units vest on September 30, 2021 and the balance vest on March 31, 2022. F3 · derivative.expiration_date: One-half of the restricted stock units vest on September 30, 2021 and the balance vest on March 31, 2022. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 16:49 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008793 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 16:09 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 1,377 | $7.26 | $9,997.02 |
DisclosureSEC source: 0001209191-19-038900 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,977 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.25 to $7.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 3,000 | $6.90 | $20,700.00 |
DisclosureSEC source: 0001209191-19-035525 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.88 to $6.92, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:17 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-19-018091 · doc4.xml · derivative · entry 3 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-07-23 F2 · derivative.exercise_date: Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:17 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018091 · doc4.xml · derivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 16:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 6,000 | $8.09 | $48,510.00 |
DisclosureSEC source: 0001209191-18-047605 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.93 to $8.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 16:10 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 1,600 | $11.97 | $19,152.00 |
DisclosureSEC source: 0001209191-18-040021 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $11.97, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.